Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 20–Sep 27, 2026)

· 1 min read

Here’s what’s on the biotech calendar for September 20–September 27: 2 FDA decision dates, 1 trial catalysts, and 0 earnings reports from tracked companies.

💊 FDA Decisions (PDUFA Dates)

Date Ticker Drug Indication Type
2026-09-22 IONS — NDA
2026-09-26 MIRM — NDA

🧪 Trial Catalysts & Milestones

  • CRDL — 2026-09-21: CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • SNDX — Phase 1 — Recruiting in 11 days, score 85/100
  • CORT — Phase 2 — Recruiting in 11 days, score 79/100
  • BHVN — Phase 2, Phase 3 — Active Trial in 11 days, score 69/100

📈 Last Week’s Biggest Gainers

  • SDGR +26.37% (volume 7.3x average)
  • BHVN +15.56% (volume 2.0x average)
  • VERA +13.22% (volume 0.5x average)
  • ARQT +11.19% (volume 2.9x average)
  • PBLS +10.85% (volume 2.4x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.